Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Oct 27, 2022

BUY
$22.17 - $51.8 $31,038 - $72,520
1,400 Added 10.37%
14,900 $769,000
Q2 2022

Jul 25, 2022

SELL
$15.36 - $27.51 $59,904 - $107,289
-3,900 Reduced 22.41%
13,500 $334,000
Q1 2022

Apr 21, 2022

BUY
$22.22 - $39.12 $86,658 - $152,568
3,900 Added 28.89%
17,400 $436,000
Q4 2021

Jan 24, 2022

BUY
$18.38 - $40.5 $18,380 - $40,500
1,000 Added 8.0%
13,500 $491,000
Q3 2021

Oct 22, 2021

SELL
$13.18 - $19.83 $492,932 - $741,641
-37,400 Reduced 74.95%
12,500 $213,000
Q2 2021

Jul 26, 2021

BUY
$9.59 - $50.88 $411,411 - $2.18 Million
42,900 Added 612.86%
49,900 $668,000
Q1 2021

Apr 23, 2021

SELL
$49.53 - $68.4 $416,052 - $574,560
-8,400 Reduced 54.55%
7,000 $358,000
Q4 2020

Jan 25, 2021

SELL
$47.25 - $65.16 $99,225 - $136,836
-2,100 Reduced 12.0%
15,400 $953,000
Q3 2020

Dec 14, 2020

BUY
$46.35 - $61.69 $241,020 - $320,788
5,200 Added 42.28%
17,500 $959,000
Q2 2020

Jul 23, 2020

BUY
$38.58 - $65.07 $462,960 - $780,839
12,000 Added 4000.0%
12,300 $707,000
Q1 2020

Apr 23, 2020

BUY
$32.73 - $50.78 $9,818 - $15,234
300 New
300 $12,000
Q4 2019

Jan 24, 2020

SELL
$6.81 - $39.55 $0 - $0
0 Closed
0 $0
Q3 2019

Oct 21, 2019

BUY
$6.47 - $8.96 $0 - $0
0 New
0 $0
Q3 2019

Oct 21, 2019

SELL
$6.47 - $8.96 $385,612 - $534,016
-59,600 Closed
0 $0
Q2 2019

Jul 25, 2019

BUY
$8.31 - $14.85 $31,578 - $56,430
3,800 Added 6.81%
59,600 $554,000
Q4 2018

Jan 23, 2019

BUY
$9.15 - $12.26 $31,110 - $41,684
3,400 Added 6.49%
55,800 $608,000
Q3 2018

Oct 19, 2018

SELL
$10.49 - $13.72 $81,822 - $107,016
-7,800 Reduced 12.96%
52,400 $662,000
Q2 2018

Aug 06, 2018

BUY
$10.62 - $13.98 $49,913 - $65,706
4,700 Added 8.47%
60,200 $792,000
Q1 2018

Apr 20, 2018

SELL
$5.9 - $14.99 $179,950 - $457,195
-30,500 Reduced 35.47%
55,500 $754,000
Q3 2017

Oct 23, 2017

BUY
$6.5 - $10.69 $559,000 - $919,340
86,000
86,000 $638,000

Others Institutions Holding CCXI

About ChemoCentryx, Inc.


  • Ticker CCXI
  • Exchange NASDAQ
  • Shares Outstandng 71,919,696
  • Market Cap $3.68M
  • Description
  • ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...
More about CCXI
Track This Portfolio

Track Strs Ohio Portfolio

Follow Strs Ohio and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

News

Stay updated on Strs Ohio with notifications on news.